The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | Targeting the N-myristoylation pathway to treat adult acute myeloid leukemia
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how the N-myristoylation pathway can be targeted as a new therapy for adult acute myeloid leukemia (AML). Pre-clinical models have shown that this pathway is overexpressed in patients with AML and can be targeted with the novel oral agent PCLX-001. PCLX-001 shall now undergo clinical investigation in patients with relapsed/refractory AML. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
